The Effect of High-flux Hemodialysis and On-line Hemodiafiltration on Endothelial Function.

Sponsor
Maimónides Biomedical Research Institute of Córdoba (Other)
Overall Status
Completed
CT.gov ID
NCT03942744
Collaborator
Instituto de Salud Carlos III (Other)
88
2
2
39.6
44
1.1

Study Details

Study Description

Brief Summary

The main aim of this project is to evaluate, in patients with chronic kidney disease (CKD5D), the role of adhesion molecules in leukocyte adhesion and transendothelial migration involved in atherogenesis. This trial is a prospective randomized crossover study in CKD5D hemodialysis patients followed in the Nephrology Unit of the Reina Sofia University Hospital (Cordoba, Spain). The estimated inclusion period is two years, with a follow-up of 24 months. Patients will be randomized to high-flux hemodialysis versus online hemodiafiltration with high convective transport (above 21 liters); after 6 months in each dialysis modality they will be switched the other technique for another 6 months. Then, patients will be maintained during 4 weeks in conventional hemodialysis "wash out period", before being started in the other dialysis modality.

Condition or Disease Intervention/Treatment Phase
  • Device: on-line hemodiafiltration
N/A

Detailed Description

The main aim of this project is to evaluate, in patients with chronic kidney disease (CKD5D), the role of adhesion molecules in leukocyte adhesion and transendothelial migration involved in atherogenesis. This trial is a prospective randomized crossover study in CKD5D hemodialysis patients followed in the Nephrology Unit of the Reina Sofia University Hospital (Cordoba, Spain). The estimated inclusion period is two years, with a follow-up of 24 months. Patients will be randomized to high-flux hemodialysis versus online hemodiafiltration with high convective transport (above 21 liters); after 6 months in each dialysis modality they will be switched the other technique for another 6 months. Then, patients will be maintained during 4 weeks in conventional hemodialysis "wash out period", before being started in the other dialysis modality. Patients will be stratified by age, gender and the presence of diabetes. Routine analytical determinations (urea, creatinine, sodium, potassium, chlorine, total CO2, calcium, phosphorus, FA, PTH, levels 25OH, β2m, ALT, hemoglobin, leukocytes, platelets, glucose, uric acid, total proteins, albumin , PCR, IL-6, ferritin, TSAT and homocysteine), characteristics of hemodialysis and dialysis dose (Kt / V and Kt) will be recorded. Residual renal function will be analysed every three months. In plasma, microRNAs profile and FGF23 levels will be determined. Markers of endothelial dysfunction (CD31 +, CD41-, CD144, CD62E) and subclinical atherosclerosis markers (CD11b, CD41 +) will be measured. The hospitalization and mortality rate due to cardiovascular causes and concurrent cardiovascular events throughout the study (acute myocardial infarction, stroke, transient ischemic attack and peripheral vascular disease) will be assessed along the study period.

Study Design

Study Type:
Interventional
Actual Enrollment :
88 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
prospective randomized crossover studyprospective randomized crossover study
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Molecular Mechanisms Involved in Cell Adhesion and Migration Process: Effect of Treatment of Chronic Kidney Disease on Endothelial Dysfunction
Actual Study Start Date :
Nov 8, 2018
Actual Primary Completion Date :
Nov 30, 2021
Actual Study Completion Date :
Feb 25, 2022

Arms and Interventions

Arm Intervention/Treatment
No Intervention: high-flux hemodialysis

high-flux hemodialysis cut-off membrane above 50

Active Comparator: on-line hemodiafiltration

postdilutional on-line hemodiafiltration with a convective transport above 21 liters

Device: on-line hemodiafiltration
on-line postdilutional hemodiafiltration with high convective transport above 21 liters

Outcome Measures

Primary Outcome Measures

  1. Effect of two different dialysis modalities (high flux vs online hemodiafiltration) on endothelial function markers: CD31,CD41,CD34; as measured by the percent of labeled cells obtained by flow cytometry. [6 months]

    These parameters will assessed, in patients with chronic kidney disease (CKD5D), Blood will be drawn before the dialysis session following the scheduled of the protocol. The measuremets of CD31 CD41 CD34 will be performend by flow cytometry according to the standard methodology described in methods.

Secondary Outcome Measures

  1. Effect of two different dialysis modalities ( high flux vs online hemodiafiltration) on hospitalization (hospital admission days/year). [6 months]

    Effect of two different dialysis modalities ( high flux vs online hemodiafiltration) on hospitalization (hospital admission days/year). Cardiovascular causes and concurrent cardiovascular events throughout the study (acute myocardial infarction, stroke, transient ischemic attack and peripheral vascular disease) will be also recorded throughout the study.

  2. Effect of two different dialysis modalities ( high flux vs online hemodiafiltration) on Serum concentration of Fibroblast Growth Factor FGF23 (pg/ml) . [6 months]

    The serum concentration of Fibroblast Growth Factor FGF23 will be quantified using commercially available ELISA Kit. (pg/ml). Blood samples will be obtained before the dialysis session.

  3. Effect of two different dialysis modalities ( high flux vs online hemodiafiltration) on vascular injury related microRNAs (relative expression) [6 months]

    The relative expression of microRNAs (126-3p, 223-3p,363-3p, 191-5p). will be determined by RTq-PCR. Blood samples will be obtained before the dialysis session.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Vascular access with a blood flow > 300ml/min

  • Age >18 <80 years written informed consent

Exclusion Criteria:
  • Neoplasia

  • B hepatitis

  • Acute or chronic inflammation life expectance less than one year Included in living donor transplant list immunosupressive drugs

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital universitario Reina Sofia Córdoba Cordoba Spain 14004
2 Alejandro Martinmalo Cordoba Córdoba Spain 14004

Sponsors and Collaborators

  • Maimónides Biomedical Research Institute of Córdoba
  • Instituto de Salud Carlos III

Investigators

  • Principal Investigator: alejandro martin-malo, MD, Maimónides Biomedical Research Institute of Córdoba

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Alejandro Martin-Malo, Professor of Medicine Chief of Dialysis Unit, Maimónides Biomedical Research Institute of Córdoba
ClinicalTrials.gov Identifier:
NCT03942744
Other Study ID Numbers:
  • PI17/01785
First Posted:
May 8, 2019
Last Update Posted:
Mar 31, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Alejandro Martin-Malo, Professor of Medicine Chief of Dialysis Unit, Maimónides Biomedical Research Institute of Córdoba
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 31, 2022